Absence of Significant Interaction Between Serum Albumin Level and Carbapenem Type on 30-Day Mortality in ESBL-positive E. coli and K. pneumoniae Bacteremia: A Multicenter Cohort Study with Inverse Probability of Treatment Weighting Analysis

Clicks: 11
ID: 321200
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #202 of 530 articles by views in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 530 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background The Infectious Diseases Society of America guidelines recommend group 2 carbapenems over ertapenem (group 1 carbapenem) for treating extended-spectrum β-lactamase (ESBL)-producing Enterobacterales infections in patients with hypoalbuminemia, but clinical evidence supporting this restriction of ertapenem is limited. We assessed whether the effect of serum albumin level on treatment outcome differed by carbapenem group in ESBL-producing bacteremia. Methods We conducted a multicenter retrospective cohort study at three hospitals, enrolling adults treated exclusively with either group 1 or group 2 carbapenems due to ESBL-positive E. coli or K. pneumoniae bacteremia (2013–2020). Baseline characteristics were balanced by inverse probability of treatment weighting (IPTW). Thirty-day mortality was analyzed using a multivariable weighted Cox proportional hazards model including an interaction term between serum albumin level and carbapenem group, and 14-day mortality was analyzed with the same interaction term in a multivariable weighted logistic regression model. Results From the 573 eligible patients, an IPTW pseudo-population of 565.1 weighted patients with good covariate balance (all standard mean differences <0.1) was analyzed (group 1 carbapenem, 374.9; group 2 carbapenem, 190.2) Overall 30-day and 14-day mortalities were 7.9% (44.9 weighted deaths) and 5.1% (29 weighted deaths), respectively. There was no significant interaction between serum albumin level and carbapenem group for either 30-day mortality (P = 0.92) or 14-day mortality (P = 0.36). Conclusion The therapeutic efficacy of ertapenem appears to be comparable to that of group 2 carbapenems for the treatment of ESBL-producing Enterobacterales bacteremia across the observed range of serum albumin levels.
Reference Key
openalex_W7169016692 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Eunju Jung, Jin Ju Park, Hong Sang Oh, Younghee Jung
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2026
DOI
10.1093/cid/ciag444
URL
https://doi.org/10.1093/cid/ciag444
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.